[go: up one dir, main page]

WO2010008150A2 - Composition pour prévenir ou traiter l'ostéoporose qui contient comme principe actif un mélange d'extraits de saururus chinensis et de scutellaria baicalensis - Google Patents

Composition pour prévenir ou traiter l'ostéoporose qui contient comme principe actif un mélange d'extraits de saururus chinensis et de scutellaria baicalensis Download PDF

Info

Publication number
WO2010008150A2
WO2010008150A2 PCT/KR2009/003648 KR2009003648W WO2010008150A2 WO 2010008150 A2 WO2010008150 A2 WO 2010008150A2 KR 2009003648 W KR2009003648 W KR 2009003648W WO 2010008150 A2 WO2010008150 A2 WO 2010008150A2
Authority
WO
WIPO (PCT)
Prior art keywords
bone
extract
osteoporosis
mixed extract
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/003648
Other languages
English (en)
Korean (ko)
Other versions
WO2010008150A3 (fr
Inventor
김영섭
유시용
연규환
홍경식
이병회
김성환
유대석
권대영
성미정
민용기
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Chemical Technology KRICT
Korea Food Research Institute KFRI
Original Assignee
Korea Research Institute of Chemical Technology KRICT
Korea Food Research Institute KFRI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Chemical Technology KRICT, Korea Food Research Institute KFRI filed Critical Korea Research Institute of Chemical Technology KRICT
Publication of WO2010008150A2 publication Critical patent/WO2010008150A2/fr
Publication of WO2010008150A3 publication Critical patent/WO2010008150A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/78—Saururaceae (Lizard's-tail family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Definitions

  • Bone is a calcified connective tissue associated with muscles.
  • the surface is a thick, hard calcified tissue that acts as a strut to balance the body and protects the organs.
  • the inside of the bone is bone marrow tissue that is the center of calcium metabolism.
  • Bone is composed of organic substances such as collagen, osteocalcin, and osteonectin, and inorganic substances such as calcium, phosphorus, and fluorine, and water. In vivo, bone formation and bone resorption are always occurring. Bone formation is promoted by a small amount of parathyroid hormone, androgen, estrogen, fluorine, phosphorus, and the like, and bone resorption is promoted by physical decompression, weightlessness, large amounts of parathyroid hormone, and corticosteroids. Therefore, the balance between them is important for bone metabolism.
  • AP-1 or NFAT specific for osteoclast differentiation can be regulated by ERK and NF- ⁇ B, which have been identified as signaling molecules that play an important role in osteoclast survival and bone resorption capacity [Takayanagi H, at al., Dev Cell. 2002 Dec; 3 (6): 889-901; Asagiri M, at al., J. Exp. Med. 2005 Nov 7; 202 (9): 1261-9.
  • RANKL blocking of signaling pathways activated by RANKL has been recognized as one of the therapeutic approaches for the treatment of bone diseases, including osteoporosis.
  • Osteoblasts originate from mesenchymal stem cells, and mineralization such as calcium formation by osteoblast differentiation not only maintains bone strength but also plays an important role in the homeostasis of calcium and hormone metabolism throughout the body. Calcium formation by osteoblast differentiation is regulated by vitamin D and parathyroid hormone, and bone formation by osteoblast differentiation is bone morphogenetic protein (BMP), Wnt, MAP within cells.
  • BMP bone morphogenetic protein
  • Saururus chinensis is a perennial herb belonging to the Saururaceae, the three hundred genus (Saururus), a herb that has long been used as a folk medicine in China.
  • Chinese herbal medicine dictionary three hundred seconds has the effect of deciduous fever, small seed detoxification, it is effective in species, each, jaundice, sediment, lobster, carbuncle, detoxification.
  • outposts, roots and leaves have been used in the private sector for the treatment of wind poison, diuresis, species, gonorrhea, hepatitis, pneumonia, venom and hypertension.
  • golden Scutellaria baicalensis
  • Scutellaria baicalensis GEORGI perennial herb belonging to the family Lamiaceae, less toxic and the main component is separated 30 species of the flavonoid compounds.
  • These pharmacological actions of gold include antipyretic, diuretic, antiviral, antibacterial, sedative, blood pressure lowering, blood sugar elevation, diarrhea ( ⁇ ⁇ ⁇ ), intestinal ( ⁇ ) exercise inhibition, anaphylaxis Anaphylaxis, anti-inflammatory, anti-allergic, anti-oxidant, and cell-immune-promoting functions are used in Korean medicine and are used in over 70 kinds of golden baths as commercial prescription drugs.
  • the extract of the three hundred seconds and gold is not only toxic, but also increase bone mineral density (BMD) and bone content (BMC) and restore the bone microstructure
  • BMD bone mineral density
  • BMC bone content
  • the mixed extract of the present invention was added to the flour, using the mixture to prepare bread, cakes, cookies, crackers and noodles to prepare foods for health promotion.
  • Black beans, black sesame seeds, and perilla were also steamed and dried in a known manner, and then roasted to prepare a powder having a particle size of 60 mesh.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne une composition destinée à prévenir ou à traiter l'ostéoporose et qui contient comme principe actif un mélange d'extraits de Saururus chinensis et de Scutellaria baicalensis. Le mélange d'extraits de Saururus chinensis et de Scutellaria baicalensis de l'invention présente les effets composites suivants: inhibition de la différenciation des ostéoclastes, accroissement de la densité osseuse et de la masse osseuse, ledit mélange rendant en même temps plus compacte la structure fine du tissu osseux. Ce mélange d'extraits possède des effets de synergie considérablement améliorés par rapport à l'utilisation individuelle de Saururus chinensis et de Scutellaria baicalensis, et peut ainsi être appliqué largement dans le domaine des fournitures médicales et des aliments diététiques pour prévenir ou traiter l'ostéoporose.
PCT/KR2009/003648 2008-07-18 2009-07-03 Composition pour prévenir ou traiter l'ostéoporose qui contient comme principe actif un mélange d'extraits de saururus chinensis et de scutellaria baicalensis Ceased WO2010008150A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080069892A KR20100009151A (ko) 2008-07-18 2008-07-18 삼백초와 황금의 혼합 추출물을 유효성분으로 함유하는골다공증 예방 또는 치료용 조성물
KR10-2008-0069892 2008-07-18

Publications (2)

Publication Number Publication Date
WO2010008150A2 true WO2010008150A2 (fr) 2010-01-21
WO2010008150A3 WO2010008150A3 (fr) 2010-03-25

Family

ID=41550806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/003648 Ceased WO2010008150A2 (fr) 2008-07-18 2009-07-03 Composition pour prévenir ou traiter l'ostéoporose qui contient comme principe actif un mélange d'extraits de saururus chinensis et de scutellaria baicalensis

Country Status (2)

Country Link
KR (1) KR20100009151A (fr)
WO (1) WO2010008150A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013147438A (ja) * 2012-01-17 2013-08-01 Kose Corp ｃＡＭＰ産生抑制剤
CN114225037A (zh) * 2022-01-29 2022-03-25 暨南大学 一种预防或治疗骨质疏松症的组合物及其制剂和用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101559937B1 (ko) * 2015-02-25 2015-10-14 주식회사 진용 홍화씨 추출물, 보스웰리아 추출물 및 황금 추출물을 유효성분으로 함유하는 뼈 길이 성장 촉진용 및 골밀도 증가용 식품 조성물
KR102113099B1 (ko) * 2018-04-06 2020-05-20 경희대학교 산학협력단 택란 추출물을 포함하는 골 질환 예방 또는 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100451444B1 (ko) * 2001-10-19 2004-10-06 이석일 아토피성 피부염 치료용 화장료 조성물
KR20030007243A (ko) * 2002-10-02 2003-01-23 김경렬 의이인, 상백피, 어성초, 길경, 생지황, 금은화, 삼백초, 생강, 진피, 적작을 주성분으로 함유하는 의약 조성물
JP2005298450A (ja) * 2004-04-15 2005-10-27 Taisho Pharmaceut Co Ltd 更年期症候群の予防又は治療剤組成物
KR100833654B1 (ko) * 2007-02-09 2008-05-29 한국화학연구원 삼백초 추출물 또는 이로부터 분리된 활성 화합물을포함하는 골다공증 예방 또는 치료용 조성물

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013147438A (ja) * 2012-01-17 2013-08-01 Kose Corp ｃＡＭＰ産生抑制剤
CN114225037A (zh) * 2022-01-29 2022-03-25 暨南大学 一种预防或治疗骨质疏松症的组合物及其制剂和用途
CN114225037B (zh) * 2022-01-29 2023-02-07 暨南大学 一种预防或治疗骨质疏松症的组合物及其制剂和用途

Also Published As

Publication number Publication date
WO2010008150A3 (fr) 2010-03-25
KR20100009151A (ko) 2010-01-27

Similar Documents

Publication Publication Date Title
US20100316741A1 (en) Composition comprising the extract of crude drug complex for stimulating bone growth
WO2012033378A2 (fr) Composition comprenant un extrait de cudrania tricuspidata et de coix lachryma-jobi ayant une activité anti-obésité et un effet d'abaissement du taux de sucre dans le sang, et son utilisation
WO2011162523A2 (fr) Composition pour prévenir ou traiter l'ostéoporose, contenant du ssangwhatang ou un produit fermenté par lactobacillus de celui-ci
WO2012050396A2 (fr) Composition pharmaceutique comprenant un extrait de plantes médicinales pour la prévention ou le traitement du cancer du foie
WO2018174448A1 (fr) Composition pour le traitement et la prévention du syndrome climactérique contenant un extrait médicinal végétal combiné d'atractylis, de mori fructus, de lyciet commun, de longane, d'achyranthes, d'écorce d'eucommia et d'asperge de cochinchine merr. comme ingrédient actif, et son utilisation
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
WO2019054758A1 (fr) Composition contenant un extrait d'alpinia oxyphylla en tant que principe actif pour la prévention, le soulagement ou le traitement de l'ostéo-arthrite
WO2016186349A2 (fr) Composition, contenant un extrait de quisaqualis indica, pour la prévention ou le traitement de l'hyperplasie prostatique
KR20230134378A (ko) 식물혼합추출분말을 유효성분으로 함유하는 근육 손실 관련 질병 예방 또는 치료용 조성물
WO2014200234A1 (fr) Composition contenant un extrait composite de rehmannia glutinosa et de pueraria lobata destinée à prévenir ou à traiter des symptômes de la ménopause
WO2010008150A2 (fr) Composition pour prévenir ou traiter l'ostéoporose qui contient comme principe actif un mélange d'extraits de saururus chinensis et de scutellaria baicalensis
WO2020153608A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de la goutte comprenant un extrait de morinda citrifolia ou de la scopolétine isolée de celui-ci en tant que principe actif
WO2016190566A9 (fr) Composition pharmaceutique ou aliment naturel fonctionnel pour la prévention et le traitement de maladies métaboliques, contenant un extrait aqueux de pleurotus eryngii var. ferulae (pf.) en tant que principe actif
KR100542876B1 (ko) 오미자 추출물을 유효성분으로 함유하는 관절염 예방 및치료용 조성물
WO2017082478A1 (fr) Composition pharmaceutique visant à prévenir ou traiter l'ostéoporose et contenant un extrait de germe de soja
WO2016010340A1 (fr) Composition pour prévenir et traiter l'inflammation ou les maladies allergiques contenant un extrait de gynura procumbens en tant que principe actif, et son utilisation
WO2021080297A1 (fr) Composition contenant un extrait de fleur d'onagre en tant que principe actif pour prévenir ou traiter l'obésité ou des syndromes métaboliques ainsi induits
WO2021040416A1 (fr) Composition pharmaceutique pour prévenir ou traiter la perte osseuse induite par des maladies métaboliques osseuses, comprenant un extrait d'artemisia scoparia en tant que principe actif
KR100555904B1 (ko) 큰느타리버섯과 오가피의 혼합 생약재 추출물 및 이를유효성분으로 하는 골다공증 예방 및 치료용 조성물
WO2018190638A1 (fr) Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max
KR102014922B1 (ko) 감초 유래 글라블리딘을 유효성분으로 하는 소화기능 개선용 조성물
WO2013022178A1 (fr) Composition pour prévention et traitement de l'obésité contenant un principe actif sous la forme d'un extrait de préparation végétale mélangée à base de lonicera japonica et d'aurantii nobilis pericarpium fermenté ou non fermenté, et son utilisation
KR20200014566A (ko) 엉겅퀴 및 우슬로 이루어진 혼합물을 함유하는 관절염의 개선, 예방 또는 치료용 조성물
WO2011019153A2 (fr) Composition pour la prévention ou le traitement de l’arthrite, contenant un extrait d’un mélange médicinal à base de plantes de schisandra chinensis baillon, scutellaria baicalensis et kalopanax pictus nakai en tant qu’ingrédient actif
WO2022154448A1 (fr) Composition comprenant un extrait composite naturel en guise de principe actif pour moduler ou renforcer l'immunité

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09798053

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09798053

Country of ref document: EP

Kind code of ref document: A2